Immunotherapy for Autoimmune Encephalitis: What Patients and Families Should Know
Autoimmune encephalitis, or AE, is a condition in which the immune system produces antibodies that attack the brain. It can cause a dramatic and frightening array of symptoms, including seizures, memory loss, psychiatric changes, involuntary movements, and even coma. For years, it was frequently mistaken for viral encephalitis, psychiatric illness, or epilepsy of unknown origin, leading to delays in diagnosis and appropriate treatment. Today, growing awareness and better antibody testing have changed the landscape, and immunotherapy has become the cornerstone of care.
A comprehensive review published in Cell Death Discovery in April 2025 by Lufeng Cheng and colleagues brings together the current state of knowledge on immunotherapy for AE, emphasizing why starting treatment early and choosing the right immunotherapy approach is critical to recovery. The review categorizes treatment into three lines, each escalating in intensity and specificity, and discusses how newer third-line therapies are opening doors for patients who previously had few options.
First-line immunotherapy, which should ideally begin before full antibody testing results return, consists of intravenous corticosteroids, intravenous immunoglobulin, and plasma exchange. These approaches work broadly to reduce inflammation and clear harmful antibodies from circulation. Many patients respond well at this stage, particularly those with anti-NMDA receptor encephalitis, the most common form. Early initiation of first-line therapy is strongly associated with better outcomes and less long-term cognitive damage.
For patients who do not improve adequately with first-line treatment, second-line options include rituximab, a drug that depletes B cells, and cyclophosphamide, a more potent immunosuppressant. Rituximab has become particularly favored for its targeted mechanism and relatively manageable side effect profile. Mycophenolate mofetil and azathioprine are also used in maintenance phases to prevent relapse.
The most exciting and challenging territory in AE treatment involves patients with refractory disease, meaning those who do not respond even to second-line therapies. Here, a newer generation of agents is showing promise. Plasma cell-targeting drugs such as bortezomib, daratumumab, and obinutuzumab can deplete the long-lived antibody-producing cells that standard treatments miss. Cytokine modulators including tocilizumab, anakinra, and tofacitinib address specific inflammatory signaling pathways. Intrathecal methotrexate, delivered directly into the fluid surrounding the brain and spinal cord, targets immune cells within the central nervous system itself.
On the symptom management front, newer anti-seizure medications including lacosamide and perampanel, which work on sodium and glutamate pathways, appear more suitable for the seizures seen in AE than older agents. The review authors note that ongoing research into the precise antibody types involved in each patient's disease will continue to guide more targeted treatment selection. For families navigating an AE diagnosis, this review reinforces that early diagnosis, rapid initiation of immunotherapy, and close neurological follow-up remain the most powerful tools available.